<unk>  is a Diagnostic Agent that is FDA approved for the diagnosis of Positron Emission Tomography (PET) imaging of the brain to estimate β amyloid neuritic plaque density in adult patients with cognitive impairment who are being evaluated for Alzheimer's disease (AD).   Common adverse reactions include flushing, headache, hypertension, nausea, and dizziness.
Flutemetamol F 18
Etofylline nicotinate
Trolamine Salicylate
Methylene Dianiline
Methaqualone
Dimethylaminopropionylphenothiazine
Fenpiverinium
Clorazepate Dipotassium